Skip to main content
Top
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Research

Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus

Authors: Tutik Sri Wahyuni, Lydia Tumewu, Adita Ayu Permanasari, Evhy Apriani, Myrna Adianti, Abdul Rahman, Aty Widyawaruyanti, Maria Inge Lusida, Achmad Fuad, Soetjipto, Nasronudin, Hiroyuki Fuchino, Nobuo Kawahara, Ikuo Shoji, Lin Deng, Chie Aoki, Hak Hotta

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

Hepatitis C virus (HCV) is a major cause of liver disease and a potential cause of substantial morbidity and mortality worldwide. The overall prevalence of HCV infection is 2%, representing 120 million people worldwide. Current standard treatment using pegylated interferon and ribavirin is effective in only 50% of the patients infected with HCV genotype 1, and is associated with significant side effects. Therefore, it is still of importance to develop new drugs for treatment of HCV. Antiviral substances obtained from natural products, including medicinal plants, are potentially good targets to study. In this study, we evaluated Indonesian medicinal plants for their anti-HCV activities.

Methods

Ethanol extracts of 21 samples derived from 17 species of medicinal plants explored in the East Java region were tested. Anti-HCV activities were determined by a cell culture method using Huh7.5 cells and HCV strains of 9 different genotypes (1a to 7a, 1b and 2b).

Results

Four of the 21 samples tested showed antiviral activities against HCV: Toona sureni leaves (TSL) with 50% inhibitory concentrations (IC50) of 13.9 and 2.0 μg/ml against the HCV J6/JFH1-P47 and -P1 strains, respectively, Melicope latifolia leaves (MLL) with IC50 of 3.5 and 2.1 μg/ml, respectively, Melanolepis multiglandulosa stem (MMS) with IC50 of 17.1 and 6.2 μg/ml, respectively, and Ficus fistulosa leaves (FFL) with IC50 of 15.0 and 5.7 μg/ml, respectively. Time-of-addition experiments revealed that TSL and MLL inhibited both at the entry and post-entry steps while MMS and FFL principally at the entry step. TSL and MLL inhibited all of 11 HCV strains of all the genotypes tested to the same extent. On the other hand, FFL showed significantly weaker inhibitory activities against the HCV genotype 1a strain, and MMS against the HCV strains of genotypes 2b and 7a to a lesser extent, compared to the other HCV genotypes.

Conclusions

Ethanol extracts of TSL, MLL, MMS and FFL showed antiviral activities against all the HCV genotypes tested with the exception that some genotype(s) showed significant resistance to FFL and to MMS to a lesser extent. These plant extracts may be good candidates for the development of anti-HCV drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moradpour D, Penin F, Rice CM: Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5: 453-463. 10.1038/nrmicro1645PubMedCrossRef Moradpour D, Penin F, Rice CM: Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5: 453-463. 10.1038/nrmicro1645PubMedCrossRef
2.
go back to reference Ploss A, Dubuisson J: New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012,61(Suppl 1):i25-i35. 10.1136/gutjnl-2012-302048PubMedCrossRef Ploss A, Dubuisson J: New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012,61(Suppl 1):i25-i35. 10.1136/gutjnl-2012-302048PubMedCrossRef
3.
go back to reference Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J: Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49: 364-377. 10.1002/hep.22673PubMedCrossRef Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J: Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49: 364-377. 10.1002/hep.22673PubMedCrossRef
4.
go back to reference Arzumanyan A, Reis HM, Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013, 13: 123-135. 10.1038/nrc3449PubMedCrossRef Arzumanyan A, Reis HM, Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013, 13: 123-135. 10.1038/nrc3449PubMedCrossRef
5.
go back to reference Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4PubMedCrossRef Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4PubMedCrossRef
6.
go back to reference Calland N, Dubuisson J, Rouille Y, Seron K: Hepatitis C virus and natural compounds: a new antiviral approach? Virus 2012, 4: 2197-2217. 10.3390/v4102197CrossRef Calland N, Dubuisson J, Rouille Y, Seron K: Hepatitis C virus and natural compounds: a new antiviral approach? Virus 2012, 4: 2197-2217. 10.3390/v4102197CrossRef
7.
go back to reference Jassim SA, Naji MA: Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003, 95: 412-427. 10.1046/j.1365-2672.2003.02026.xPubMedCrossRef Jassim SA, Naji MA: Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003, 95: 412-427. 10.1046/j.1365-2672.2003.02026.xPubMedCrossRef
8.
go back to reference Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K: Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res 2000, 14: 510-516. 10.1002/1099-1573(200011)14:7<510::AID-PTR646>3.0.CO;2-BPubMedCrossRef Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K: Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res 2000, 14: 510-516. 10.1002/1099-1573(200011)14:7<510::AID-PTR646>3.0.CO;2-BPubMedCrossRef
9.
go back to reference Wu SF, Lin CK, Chuang YS, Chang FR, Tseng CK, Wu YC, Lee JC: Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. J Viral Hepat 2012, 19: 364-370. 10.1111/j.1365-2893.2011.01558.xPubMedCrossRef Wu SF, Lin CK, Chuang YS, Chang FR, Tseng CK, Wu YC, Lee JC: Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. J Viral Hepat 2012, 19: 364-370. 10.1111/j.1365-2893.2011.01558.xPubMedCrossRef
10.
go back to reference Ravikumar YS, Ray U, Nandhitha M, Perween A, Raja Naika H, Khanna N, Das S: Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as potent natural source. Virus Res 2011, 158: 89-97. 10.1016/j.virusres.2011.03.014PubMedCrossRef Ravikumar YS, Ray U, Nandhitha M, Perween A, Raja Naika H, Khanna N, Das S: Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as potent natural source. Virus Res 2011, 158: 89-97. 10.1016/j.virusres.2011.03.014PubMedCrossRef
11.
go back to reference Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh GK, Maloney EM, Wang J, Dasgupta A, French SW: Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology 2012, 433: 346-355. 10.1016/j.virol.2012.08.029PubMedPubMedCentralCrossRef Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh GK, Maloney EM, Wang J, Dasgupta A, French SW: Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology 2012, 433: 346-355. 10.1016/j.virol.2012.08.029PubMedPubMedCentralCrossRef
12.
go back to reference Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R: Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 2012, 19: e81-e88. 10.1111/j.1365-2893.2011.01507.xPubMedCrossRef Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R: Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 2012, 19: e81-e88. 10.1111/j.1365-2893.2011.01507.xPubMedCrossRef
13.
go back to reference Nugraha AS, Keller PA: Revealing indigenous Indonesian traditional medicine: anti-infective agents. Nat Prod Commun 2011, 6: 1953-1966.PubMed Nugraha AS, Keller PA: Revealing indigenous Indonesian traditional medicine: anti-infective agents. Nat Prod Commun 2011, 6: 1953-1966.PubMed
14.
go back to reference Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide YH, Deng L, Hotta H: Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 2009, 90: 1681-1691. 10.1099/vir.0.010983-0PubMedCrossRef Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide YH, Deng L, Hotta H: Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 2009, 90: 1681-1691. 10.1099/vir.0.010983-0PubMedCrossRef
15.
go back to reference Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005, 309: 623-626. 10.1126/science.1114016PubMedCrossRef Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005, 309: 623-626. 10.1126/science.1114016PubMedCrossRef
16.
go back to reference Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11: 791-796. 10.1038/nm1268PubMedPubMedCentralCrossRef Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11: 791-796. 10.1038/nm1268PubMedPubMedCentralCrossRef
17.
go back to reference Nawawi A, Nakamura N, Hattori M, Kurokawa M, Shiraki K: Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Phytother Res 1999, 13: 37-41. 10.1002/(SICI)1099-1573(199902)13:1<37::AID-PTR382>3.0.CO;2-SPubMedCrossRef Nawawi A, Nakamura N, Hattori M, Kurokawa M, Shiraki K: Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Phytother Res 1999, 13: 37-41. 10.1002/(SICI)1099-1573(199902)13:1<37::AID-PTR382>3.0.CO;2-SPubMedCrossRef
18.
go back to reference O'Donnell F, Ramachandran VN, Smyth TJ, Smyth WF, Brooks P: An investigation of bioactive phytochemicals in the leaves of Melicope vitiflora by electrospray ionisation ion trap mass spectrometry. Anal Chim Acta 2009, 634: 115-120. 10.1016/j.aca.2008.11.066PubMedCrossRef O'Donnell F, Ramachandran VN, Smyth TJ, Smyth WF, Brooks P: An investigation of bioactive phytochemicals in the leaves of Melicope vitiflora by electrospray ionisation ion trap mass spectrometry. Anal Chim Acta 2009, 634: 115-120. 10.1016/j.aca.2008.11.066PubMedCrossRef
19.
go back to reference Higa M, Imamura M, Ogihara K, Suzuka T: Isolation of five new flavonoids from Melicope triphylla. Chem Pharm Bull (Tokyo) 2013, 61: 384-389. 10.1248/cpb.c12-00940CrossRef Higa M, Imamura M, Ogihara K, Suzuka T: Isolation of five new flavonoids from Melicope triphylla. Chem Pharm Bull (Tokyo) 2013, 61: 384-389. 10.1248/cpb.c12-00940CrossRef
20.
go back to reference Haid S, Novodomska A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, et al.: A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 2012, 14: 213-222 e215.CrossRef Haid S, Novodomska A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, et al.: A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 2012, 14: 213-222 e215.CrossRef
21.
go back to reference Li Y, Yu S, Liu D, Proksch P, Lin W: Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L. Bioorg Med Chem Lett 2012, 22: 1099-1102. 10.1016/j.bmcl.2011.11.109PubMedCrossRef Li Y, Yu S, Liu D, Proksch P, Lin W: Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L. Bioorg Med Chem Lett 2012, 22: 1099-1102. 10.1016/j.bmcl.2011.11.109PubMedCrossRef
22.
go back to reference Kuete V, Ngameni B, Simo CC, Tankeu RK, Ngadjui BT, Meyer JJ, Lall N, Kuiate JR: Antimicrobial activity of the crude extracts and compounds from Ficus chlamydocarpa and Ficus cordata (Moraceae). J Ethnopharmacol 2008, 120: 17-24. 10.1016/j.jep.2008.07.026PubMedCrossRef Kuete V, Ngameni B, Simo CC, Tankeu RK, Ngadjui BT, Meyer JJ, Lall N, Kuiate JR: Antimicrobial activity of the crude extracts and compounds from Ficus chlamydocarpa and Ficus cordata (Moraceae). J Ethnopharmacol 2008, 120: 17-24. 10.1016/j.jep.2008.07.026PubMedCrossRef
23.
go back to reference Lazreg Aref H, Gaaliche B, Fekih A, Mars M, Aouni M, Pierre Chaumon J, Said K: In vitro cytotoxic and antiviral activities of Ficus carica latex extracts. Nat Prod Res 2011, 25: 310-319. 10.1080/14786419.2010.528758PubMedCrossRef Lazreg Aref H, Gaaliche B, Fekih A, Mars M, Aouni M, Pierre Chaumon J, Said K: In vitro cytotoxic and antiviral activities of Ficus carica latex extracts. Nat Prod Res 2011, 25: 310-319. 10.1080/14786419.2010.528758PubMedCrossRef
24.
go back to reference Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D, Huleihel M: Antiviral activity of ethanol extracts of Ficus binjamina and Lilium candidum in vitro. N Biotechnol 2009, 26: 307-313. 10.1016/j.nbt.2009.08.005PubMedCrossRef Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D, Huleihel M: Antiviral activity of ethanol extracts of Ficus binjamina and Lilium candidum in vitro. N Biotechnol 2009, 26: 307-313. 10.1016/j.nbt.2009.08.005PubMedCrossRef
25.
go back to reference Yarmolinsky L, Huleihel M, Zaccai M, Ben-Shabat S: Potent antiviral flavone glycosides from Ficus benjamina leaves. Fitoterapia 2012, 83: 362-367. 10.1016/j.fitote.2011.11.014PubMedCrossRef Yarmolinsky L, Huleihel M, Zaccai M, Ben-Shabat S: Potent antiviral flavone glycosides from Ficus benjamina leaves. Fitoterapia 2012, 83: 362-367. 10.1016/j.fitote.2011.11.014PubMedCrossRef
26.
go back to reference Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouille Y, Seron K: (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012, 55: 720-729. 10.1002/hep.24803PubMedCrossRef Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouille Y, Seron K: (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012, 55: 720-729. 10.1002/hep.24803PubMedCrossRef
27.
go back to reference Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, et al.: Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51: 1912-1921. 10.1002/hep.23587PubMedPubMedCentralCrossRef Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, et al.: Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51: 1912-1921. 10.1002/hep.23587PubMedPubMedCentralCrossRef
28.
go back to reference Barcena R, Moreno A, Rodriguez-Gandia MA, Albillos A, Arocena C, Blesa C, Garcia-Hoz F, Graus J, Nuno J, Lopez-Hervas P, et al.: Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013, 58: 421-426. 10.1016/j.jhep.2012.10.009PubMedCrossRef Barcena R, Moreno A, Rodriguez-Gandia MA, Albillos A, Arocena C, Blesa C, Garcia-Hoz F, Graus J, Nuno J, Lopez-Hervas P, et al.: Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013, 58: 421-426. 10.1016/j.jhep.2012.10.009PubMedCrossRef
29.
go back to reference Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, Hotta H: Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol 2008, 82: 10375-10385. 10.1128/JVI.00395-08PubMedPubMedCentralCrossRef Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, Hotta H: Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol 2008, 82: 10375-10385. 10.1128/JVI.00395-08PubMedPubMedCentralCrossRef
Metadata
Title
Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus
Authors
Tutik Sri Wahyuni
Lydia Tumewu
Adita Ayu Permanasari
Evhy Apriani
Myrna Adianti
Abdul Rahman
Aty Widyawaruyanti
Maria Inge Lusida
Achmad Fuad
Soetjipto
Nasronudin
Hiroyuki Fuchino
Nobuo Kawahara
Ikuo Shoji
Lin Deng
Chie Aoki
Hak Hotta
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-259

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine